Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum)

Inclusion Criteria: * Documented chronic pancreatitis, alcohol induced chronic pancreatitis or cystic fibrosis * Documented pancreatic enzyme insufficiency as determined by spot fecal elastase-1 \<75 mcg/g stool at the time of inclusion in the study * Required daily exogenous enzyme supplementation with commercially available pancreatic enzymes * \> 18 years of age * Male and female subjects qualify * Able to swallow capsules * Clinically stable with no evidence of an acute medical condition * History of steatorrhea Exclusion Criteria: * History of fibrosing colonopathy in CF subjects * Current diagnosis or a history of distal intestinal obstruction syndrome (DIOS) in the past 4 months * Known contraindication, sensitivity or hypersensitivity to porcine pancreatic enzymes * Active liver disease * ALT or AST \>3 times the upper limit of normal * Bilirubin \>3 times the upper limit of normal * Acute pancreatitis or acute exacerbation of chronic pancreatitis * Acute treatment with any systemic (oral or IV) antibiotics two weeks prior to screening * Subjects on erythromycin unwilling to discontinue the treatment two weeks prior to screening * Receiving treatment with antacids or H2 receptor blockers or proton pump inhibitors and unable to discontinue these treatments prior to day 1 * Inability to cooperate with or non-compliant with required study procedures * Pregnant, breast feeding * Current daily prescribed scheduled use of narcotics (patients requiring PRN use of narcotics are not excluded) * Poorly controlled diabetes * A medical condition which the investigator deems significant enough to interfere with the ability of the subject to participate in the intubation study or interfering with assessment or enzyme bioavailability * Stomach pH \> 4 * Small bowel disease (i.e. celiac disease)